Article: Don’t Let QALY Restrict Life-Saving Drugs

Gunnar Esiason, an MBA/MPH candidate at the Dartmouth Tuck School of Business, in a recent article published on The Hill says access to life-saving medication shouldn’t be determined by the quality-adjusted life year (QALY), a “discriminatory economic model.”

“I call on policymakers to listen to people living with debilitating illnesses and not to put our fates in the hands of a discriminatory economic model,” Esiason writes. “We must preserve access to breakthrough medications, the innovative track that delivers these medications, and, ultimately, make sure that out of pocket costs are low for patients and families.”

To read the full article, click here.